These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 25017425)

  • 21. HIV preexposure prophylaxis in the real world.
    Daskalakis DC
    Top Antivir Med; 2014; 22(4):670-5. PubMed ID: 25398067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pre-exposure prophylaxis for HIV transmission? No, unless].
    Boeke AJ; Heijnen AM
    Ned Tijdschr Geneeskd; 2013; 157(27):A6359. PubMed ID: 23838404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.
    Liegler T; Abdel-Mohsen M; Bentley LG; Atchison R; Schmidt T; Javier J; Mehrotra M; Eden C; Glidden DV; McMahan V; Anderson PL; Li P; Wong JK; Buchbinder S; Guanira JV; Grant RM;
    J Infect Dis; 2014 Oct; 210(8):1217-27. PubMed ID: 24740633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in Northern Thailand.
    Yang D; Chariyalertsak C; Wongthanee A; Kawichai S; Yotruean K; Saokhieo P; Guadamuz T; Suwanvanichkij V; Beyrer C; Chariyalertsak S
    PLoS One; 2013; 8(10):e76650. PubMed ID: 24116132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Costs and benefits of on-demand HIV preexposure prophylaxis in MSM.
    Durand-Zaleski I; Mutuon P; Charreau I; Tremblay C; Rojas D; Pialoux G; Chidiac C; Capitant C; Spire B; Cotte L; Chas J; Meyer L; Molina JM;
    AIDS; 2018 Jan; 32(1):95-102. PubMed ID: 29210777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Knowledge of and opinions on HIV preexposure prophylaxis among front-line service providers at Canadian AIDS service organizations.
    Senn H; Wilton J; Sharma M; Fowler S; Tan DH
    AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1183-9. PubMed ID: 23731254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acceptability of pre-exposure prophylaxis for HIV prevention: facilitators, barriers and impact on sexual risk behaviors among men who have sex with men in Benin.
    Ahouada C; Diabaté S; Mondor M; Hessou S; Guédou FA; Béhanzin L; Batona G; Gning NN; Zannou DM; Alary M
    BMC Public Health; 2020 Aug; 20(1):1267. PubMed ID: 32819335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
    de Lastours V; Fonsart J; Burlacu R; Gourmel B; Molina JM
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4905-7. PubMed ID: 21788466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
    Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.
    Hosek SG; Landovitz RJ; Kapogiannis B; Siberry GK; Rudy B; Rutledge B; Liu N; Harris DR; Mulligan K; Zimet G; Mayer KH; Anderson P; Kiser JJ; Lally M; Brothers J; Bojan K; Rooney J; Wilson CM
    JAMA Pediatr; 2017 Nov; 171(11):1063-1071. PubMed ID: 28873128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
    Corneli AL; Deese J; Wang M; Taylor D; Ahmed K; Agot K; Lombaard J; Manongi R; Kapiga S; Kashuba A; Van Damme L;
    J Acquir Immune Defic Syndr; 2014 Jul; 66(3):324-31. PubMed ID: 25157647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
    JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on HIV prevention and preexposure prophylaxis.
    Baker J; Rolls J
    JAAPA; 2020 Jun; 33(6):12-17. PubMed ID: 32384293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Could FDA approval of pre-exposure prophylaxis make a difference? A qualitative study of PrEP acceptability and FDA perceptions among men who have sex with men.
    Underhill K; Morrow KM; Operario D; Mayer KH
    AIDS Behav; 2014 Feb; 18(2):241-9. PubMed ID: 23673790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Considerations regarding antiretroviral chemoprophylaxis in MSM.
    Poynten IM; Zablotska I; Grulich AE
    Curr Opin HIV AIDS; 2012 Nov; 7(6):549-56. PubMed ID: 22918448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
    Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
    N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
    Mugo NR; Hong T; Celum C; Donnell D; Bukusi EA; John-Stewart G; Wangisi J; Were E; Heffron R; Matthews LT; Morrison S; Ngure K; Baeten JM;
    JAMA; 2014 Jul 23-30; 312(4):362-71. PubMed ID: 25038355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.
    Cambiano V; Miners A; Dunn D; McCormack S; Ong KJ; Gill ON; Nardone A; Desai M; Field N; Hart G; Delpech V; Cairns G; Rodger A; Phillips AN
    Lancet Infect Dis; 2018 Jan; 18(1):85-94. PubMed ID: 29054789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study on Pre-Exposure Prophylaxis Regimens among Men Who Have Sex with Men: A Prospective Cohort Study.
    Wu D; Tao H; Dai J; Liang H; Huang A; Zhong X
    Int J Environ Res Public Health; 2019 Dec; 16(24):. PubMed ID: 31818006
    [No Abstract]   [Full Text] [Related]  

  • 40. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.
    Sagaon-Teyssier L; Suzan-Monti M; Demoulin B; Capitant C; Lorente N; Préau M; Mora M; Rojas Castro D; Chidiac C; Chas J; Meyer L; Molina JM; Spire B;
    AIDS Care; 2016; 28 Suppl 1(sup1):48-55. PubMed ID: 26883400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.